Lyra Therapeutics, Inc. Q4 FY2020 earnings call

• Recently appointed Dr. Robert Kern as Chief Medical Officer, a renowned Otolaryngologist with expertise in chronic rhinosinusitis. - Appointed Dr. Nancy Snyderman to the Board of Directors, leveraging her ENT experience. - LANTERN Phase 2 trial results released in December 2020, showing statistically significant improvement in CRS symptoms for the 7,500 micrograms dose at 24 weeks. - Completion of enrollment in the 24-patient pharmacokinetic clinical study for LYR-220 despite COVID-19. - Plan to initiate Phase 2 study for LYR-220 in the second half of 2021, using the 7500 microgram dose. - Intend to present full LANTERN dataset at COSM in April 2021, including results on individual cardinal symptoms, MRI inflammation data, and results for polyp and non-polyp patients. - Sufficient cash to fund operations into 2023.

No detailed segment performance breakdown by revenue contribution is provided in the transcript as it focuses on product candidates for chronic rhinosinusitis without specific revenue percentage data for segments.

• Lyra believes it has sufficient cash to fund operations through planned activities into 2023. - Plan to have a hybrid reimbursement and distribution model incorporating buy and bill and specialty pharmacy. - Anticipate initiating pivotal Phase 3 trial for LYR-210 at the end of 2021 after end of Phase 2 meeting with FDA. - Expect to announce results from the 56-day U.S. PK study of LYR-220 in the second quarter of 2021.

• Uncertainties related to clinical development and regulatory approval processes. - Impact of COVID-19 on enrollment and operations. - Risks associated with forward-looking statements, as actual results may differ materially from expectations.

Q: What new information will be presented at CASM regarding the LANTERN study?

A: Will present data on each cardinal symptom of Chronic Rhinosinusitis (nasal obstruction, nasal discharge, facial pain, smell), results on individual symptoms, composite of three cardinal symptoms, MRI inflammation data, and results for patients with and without polyps.

Q: What is Lyra's reimbursement strategy?

A: Hybrid approach incorporating both buy and bill model and specialty pharmacy, to accommodate different physician and payer preferences.

Q: With Dr. Kern's arrival, any changes to the Phase 3 study for LYR-210?

A: Primary endpoint will be cardinal symptoms, likely using 24-week time point, similar inclusion/exclusion to Phase 2; details to be determined after end of Phase 2 meeting with FDA.

Q: Design of the pharmacokinetics study for LYR-220 and what constitutes a win?

A: Enrolled 24 patients (12 at 2,500 micrograms, 12 at 7,500 micrograms); results to be announced in Q2 2021, focusing on characterizing mometasone furoate levels in blood as required for NDA.

Q: Why no financial guidance for 2021?

A: Focus on ongoing clinical trials, tech transfer, and it's more meaningful to provide cash guidance covering into 2023 rather than specific annual guidance.

Q: FDA meeting schedule and agenda?

A: Scheduled before end of second quarter; agenda includes reviewing LANTERN study results and proposing plans for Phase 3, seeking FDA feedback.

Q: Efficacy of individual cardinal symptoms in LANTERN and Dr. Kern's reason for joining Lyra?

A: LANTERN showed improvement in individual cardinal symptoms; Dr. Kern joined for the potential of LYR-210 to change CRS treatment by providing six-month duration, aligning with his clinical experience and desire to impact patient care.